Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

Authors

null

Laura Spring

Massachusetts General Hospital Cancer Center, Boston, MA

Laura Spring , Shom Goel , Sara Sutherland , Jeffrey G. Supko , Dejan Juric , Steven J. Isakoff , Erica L. Mayer , Beverly Moy , Sara M. Tolaney , Aditya Bardia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT02657343

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1028)

DOI

10.1200/JCO.2019.37.15_suppl.1028

Abstract #

1028

Poster Bd #

109

Abstract Disclosures